Kiniksa (KNSA) Stock: Why It Rose 21% After Earnings

Quick answer

Kiniksa Pharmaceuticals rose 21.0% to $88.28 at 11:59am ET on Oct 27, 2026, from a $72.98 close, after it reported third-quarter sales of Arcalyst, its drug for recurrent pericarditis, of $286.0 million, up about 58% from $180.9 million a year earlier. It also raised its 2026 Arcalyst sales guidance to $1.045 billion to $1.050 billion, from $980 million to $995 million, so the drug will pass $1 billion in annual sales this year. The quarter came in about $25 million above the average analyst estimate of about $261 million, and diluted earnings of $0.56 a share compared with an average estimate of $0.37. The biotech fund XBI was up 2.2% at the same time.

Our view: Bullish through December 31, 2026, the end of the year the new guidance covers and Kiniksa's deadline to start a Phase 1 trial of KPL-1161. The three strongest facts for the stock: growth is speeding up, not slowing, with year-over-year sales growth of about 58% in the third quarter against about 55% in the second; the 2026 range has now been raised three times, from $900 million to $920 million in February, and the share of eligible patients on the drug rose to about 23% from about 18% at the end of 2025, so the base keeps widening; and the company is profitable, with $47.3 million of quarterly net income and $568.8 million of cash and no debt, so there is no funding overhang. The three strongest against: the shares now trade at more than 60 times trailing earnings and above the average analyst target of $86.40; almost all revenue comes from one drug; and the next new drug, KPL-387, has no pivotal data until the second half of 2027. The first set carries more weight through year-end, because no scheduled event before December 31 can test the valuation, while the raised range sets a fourth-quarter bar of about $301 million to $306 million that the third-quarter trend already points toward, and analysts tend to lift targets that the price has passed. We would move off Bullish if Kiniksa cuts or narrows the 2026 range below $1.045 billion, if the KPL-1161 Phase 1 start slips past the end of 2026, or if the shares close below $72.98, the Oct 26 close, which would erase the reaction. This is a view on direction over that window, not a recommendation to trade the stock.

Kiniksa daily closing price from Sep 14 to Oct 27, 2026, with the record close, the pre-earnings low and the results marked

Key takeaways

Kiniksa rose 21.0% to $88.28 at 11:59am ET on Oct 27, 2026, from a $72.98 close, after third-quarter Arcalyst sales of $286.0 million, up about 58% from a year earlier; it opened at $84.52 and set a 52-week high of $88.44.
Kiniksa raised its 2026 Arcalyst sales guidance to $1.045 billion to $1.050 billion from $980 million to $995 million, the third raise this year from a February range of $900 million to $920 million.
Net income rose to $47.3 million, or $0.56 a diluted share, from $18.4 million, and cash reached $568.8 million with no debt.
The jump also undid a pre-earnings slide: the stock fell 12.3% from a record $83.17 close on Oct 20 to $72.98 on Oct 26.
Our view is Bullish through December 31, 2026, the end of the guidance year and the deadline Kiniksa set to start a Phase 1 trial of KPL-1161; the risk is a valuation above 60 times trailing earnings and reliance on one drug.

Table of contents

Oct 27, 2026: a gap higher at the open and a new 52-week high
The numbers
The bull case
The risks
What comes next

Oct 27, 2026: a gap higher at the open and a new 52-week high

Kiniksa released results before the open, at 7:30am ET, and held its call at 8:30am. The stock opened at $84.52, 15.8% above Monday's close. Its low for the session was $82.26, which still left it 12.7% higher on the day, and it reached $88.44, a new 52-week high. At 11:59am it was $88.28 on about 1.0 million shares, already more than its 20-day average for a full day.

The jump also reversed a slide into the report. The shares closed at a record $83.17 on Oct 20, then fell in three of the next four sessions to $72.98 on Oct 26, a drop of 12.3%, including a 4.0% fall on Oct 26 on 1.4 million shares. Kiniksa's only filing in that window named its chief operating officer as president. Part of today's move was that pre-earnings caution unwinding: measured from the Oct 20 record, the stock was up about 6%. After the move, RSI(14) stood at about 64, the shares sat about 13% above their 50-day average and about 49% above their 200-day average, and they traded within 0.2% of the 52-week high. More of the day's big moves are in today's biggest stock moves.

The numbers

What Kiniksa reported for the quarter ended Sept 30:

Sales. Arcalyst net product revenue of $286.0 million, up 17% from $243.6 million in the second quarter and about 58% from a year earlier. Nine-month sales were $743.8 million, against $475.4 million a year earlier.
Profit. Operating income of $54.2 million, against $24.0 million a year earlier. Net income was $47.3 million, or $0.56 a diluted share, against $18.4 million, or $0.23.
Costs. Collaboration expenses, which the company says are driven mainly by Arcalyst's collaboration profitability, rose to $105.8 million from $63.3 million. Research spending rose to $32.8 million from $24.2 million on more KPL-387 trial work, and selling, general and administrative costs rose to $65.4 million from $49.1 million.
Cash. $568.8 million of cash, cash equivalents and short-term investments at Sept 30, up from $525.9 million at June 30 and $414.1 million at the end of 2025, with no debt.
Adoption. About 23% of the 14,000 patients a year with multiple recurrences were on Arcalyst, against about 21% at the end of June. More than 5,450 prescribers have written it, against more than 5,000 in July. Average total time on therapy was about three years.

Bar chart of Arcalyst quarterly net product revenue: $180.9 million in Q3 2025, $202.1 million in Q4 2025, $214.3 million in Q1 2026, $243.6 million in Q2 2026 and $286.0 million in Q3 2026

The guidance tells the same story. Kiniksa has raised its 2026 Arcalyst range at every report this year:

Date	2026 Arcalyst sales guidance	Midpoint
Feb 24, 2026	$900M to $920M	$910M
Apr 28, 2026	$930M to $945M	$937.5M
Jul 28, 2026	$980M to $995M	$987.5M
Oct 27, 2026	$1,045M to $1,050M	$1,047.5M

The midpoint is now 15% above where it started the year. Our guide to why guidance changes move stocks explains why a raised outlook often matters more than the quarter itself. Kiniksa also set 2026 research spending at $160 million to $170 million and selling, general and administrative costs at $270 million to $280 million.

The bull case

Growth is not fading. Sales rose 17% from the second quarter alone. Years into its launch in this disease, the drug is still gaining share.
Room to grow. With about 23% of eligible patients on treatment, most of the market is still untreated with Arcalyst, and patients stay on it for about three years.
Estimates have to move. A quarter about $25 million above the average estimate and a higher full-year range push forecasts up; our page on earnings estimate revisions covers why that tends to support a stock after the first day.
A next product in the same disease. KPL-387 targets once-monthly dosing in a liquid formulation, against weekly Arcalyst, and is in a pivotal trial of up to about 85 patients.

The risks

Valuation. At $88.28 the market value is about $6.9 billion, more than 60 times trailing earnings and about 7 times trailing sales. That leaves less room for a soft quarter.
One product. Arcalyst is all of Kiniksa's product revenue, and a large share of its profit is shared through collaboration expenses, which rose 67% from a year earlier, faster than sales.
A long wait for new data. KPL-387 pivotal results are not due until the second half of 2027, and the trial is event-driven, so timing can move.
The run-up. The stock was $35.20 at its 52-week low. A 150% rise from there means holders have large gains to protect.

What comes next

KPL-1161 Phase 1 start, by the end of 2026. Kiniksa has kept this target since February.
Fourth-quarter results, likely in late February 2027 (last year's came on Feb 24). The bar is about $301 million to $306 million of Arcalyst sales, implied by the new range; reading the release line by line is covered in our guide on how to read an earnings release.
KPL-387 pivotal data, second half of 2027. Our explainer on regulatory approvals as catalysts covers how the steps after that data tend to move a stock.

Frequently asked questions

Why is Kiniksa stock up today?

Kiniksa reported third-quarter Arcalyst net sales of $286.0 million, up about 58% from $180.9 million a year earlier, and raised its 2026 Arcalyst sales guidance to $1.045 billion to $1.050 billion. The stock rose 21.0% to $88.28 at 11:59am ET on Oct 27.

What is Arcalyst?

Arcalyst (rilonacept) is a weekly injection that blocks the inflammatory signals IL-1 alpha and IL-1 beta. It was discovered by Regeneron and is approved by the FDA for recurrent pericarditis, an inflammation of the sac around the heart that keeps coming back, and for two rare inherited inflammatory conditions.

How many patients take Arcalyst?

At the end of the third quarter about 23% of the 14,000 patients a year with multiple pericarditis recurrences were on Arcalyst, up from about 18% at the end of 2025. More than 5,450 prescribers have written it for recurrent pericarditis, against more than 4,150 at the end of 2025.

Is Kiniksa profitable?

Yes. Third-quarter net income was $47.3 million, or $0.56 a diluted share, against $18.4 million a year earlier. Kiniksa had $568.8 million of cash, cash equivalents and short-term investments at Sept 30 and no debt, and it expects its operating plan to stay cash flow positive on an annual basis.

What does the 2026 guidance imply for the fourth quarter?

Sales were $743.8 million in the first nine months, so the new $1.045 billion to $1.050 billion range implies fourth-quarter Arcalyst sales of about $301 million to $306 million, against $286.0 million in the third quarter and $202.1 million in the fourth quarter of 2025.

When will KPL-387 data come?

Kiniksa expects pivotal Phase 3 data for KPL-387, a once-monthly injection for recurrent pericarditis, in the second half of 2027, with a goal of reaching patients in 2028 or 2029. It plans to start a Phase 1 trial of KPL-1161, a candidate aimed at quarterly dosing, by the end of 2026.

Sources

Article details

By James Whitfield, Head of Equity Research, Dombey Capital

Published October 27, 2026 · 6 min read · Event-Driven Investing